These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 18444846)

  • 1. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia.
    Daneman N; Low DE; McGeer A; Green KA; Fisman DN
    Clin Infect Dis; 2008 Apr; 46(8):1131-8. PubMed ID: 18444846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.
    Lynch III JP; Martinez FJ
    Clin Infect Dis; 2002 Mar; 34 Suppl 1():S27-46. PubMed ID: 11810608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?
    Rothermel CD
    Clin Infect Dis; 2004 May; 38 Suppl 4():S346-9. PubMed ID: 15127368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of bacterial resistance to macrolides.
    Halpern MT; Schmier JK; Snyder LM; Asche C; Sarocco PW; Lavin B; Nieman R; Mandell LA
    J Antimicrob Chemother; 2005 May; 55(5):748-57. PubMed ID: 15772147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
    Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
    Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance.
    Martin M; Quilici S; File T; Garau J; Kureishi A; Kubin M
    J Antimicrob Chemother; 2007 May; 59(5):977-89. PubMed ID: 17395688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Community acquired pneumonia; no reason to revise current Dutch antibiotic guidelines].
    Oosterheert JJ; Bonten MJ; Schneider MM; Hoepelman IM
    Ned Tijdschr Geneeskd; 2003 Mar; 147(9):381-6. PubMed ID: 12661455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
    Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
    J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
    Charles PG; Whitby M; Fuller AJ; Stirling R; Wright AA; Korman TM; Holmes PW; Christiansen KJ; Waterer GW; Pierce RJ; Mayall BC; Armstrong JG; Catton MG; Nimmo GR; Johnson B; Hooy M; Grayson ML;
    Clin Infect Dis; 2008 May; 46(10):1513-21. PubMed ID: 18419484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia.
    Earnshaw SR; Candrilli SD; Fernandes AW; Higashi MK
    Manag Care Interface; 2005 Oct; 18(10):36-44. PubMed ID: 16265933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand.
    Reechaipichitkul W; Assawasanti K; Chaimanee P
    Southeast Asian J Trop Med Public Health; 2006 Mar; 37(2):320-6. PubMed ID: 17124993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antibiotic therapy for community acquired Streptococcus pneumoniae pneumonia: clinical relevance of antibiotic resistance].
    Bédos JP; Bruneel F
    Med Mal Infect; 2006; 36(11-12):667-79. PubMed ID: 16842956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.
    Jacobs MR
    Clin Infect Dis; 2002 Sep; 35(5):565-9. PubMed ID: 12173130
    [No Abstract]   [Full Text] [Related]  

  • 15. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management.
    Daneman N; McGeer A; Green K; Low DE;
    Clin Infect Dis; 2006 Aug; 43(4):432-8. PubMed ID: 16838231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Streptococcus pneumoniae: does antimicrobial resistance matter?
    Lynch JP; Zhanel GG
    Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative.
    Nuermberger E; Bishai WR
    Clin Infect Dis; 2004 Jan; 38(1):99-103. PubMed ID: 14679455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acute community-acquired pneumonia. A review of clinical trials].
    Chidiac C
    Med Mal Infect; 2006; 36(11-12):650-66. PubMed ID: 16876363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of health care resource utilization after macrolide treatment failure: results from a large, population-based cohort with acute sinusitis, acute bronchitis, and community-acquired pneumonia.
    Wu JH; Howard DH; McGowan JE; Frau LM; Dai WS
    Clin Ther; 2004 Dec; 26(12):2153-62. PubMed ID: 15823779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.